The Symptoms Of Multiple Sclerosis Blog

If you're new here, you may want to subscribe to my RSS feed. Thanks for visiting!

An anthology of original short stories, poetry and personal accounts, MS Talent Volume 2, is set to benefit four charities supporting people with Multiple Sclerosis and raise awareness of the condition, which affects 85,000 people in the UK.

New research may help reveal why different parts of the brain can come under attack in patients with multiple sclerosis (MS). According to a new study in mice with an MS-like disease, the brain’s response to a protein produced by invading T cells dictates whether it’s the spinal cord or cerebellum that comes under fire. The study - from researchers at the University of Maryland School of Medicine in Baltimore and Washington University in St.

A Glasgow-based research lab has announced what it claims to be a major breakthrough in the treatment of progressive multiple sclerosis (MS). Glasgow Health Solutions (GHS), headed by Dr Tom Gilhooly, has developed Tyscore Assay, a blood test which detects the chemicals associated with the deterioration of nerve cells in people with MS.

Scientists at the University of Leeds have developed a hand-held device that they claim can test for serious conditions including multiple sclerosis (MS), using a tiny sample of blood or urine. If trials are successful the researchers hope the technology could be available in three to five years. The device works by looking for tell-tale signs of a condition from the molecules present in the blood (called biomarkers).

A protein that helps keep immune cells quiet is more abundant in the spinal fluid of patients with multiple sclerosis (MS), further boosting suspicion that the protein, TREM-2, may be an important contributor to the disease. More of an immune-control protein might seem like a boon to MS sufferers, whose symptoms are caused by misdirected immune attacks on the protective lining that coats nerve cell branches. But researchers at Washington University School of Medicine in St.

The majority of children vaccinated against hepatitis B are not at an increased risk of developing multiple sclerosis (MS), according to a study to be published in the October 8, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study based in France involved 349 children with MS and 2,941 children without the disease. The children were all under the age of 16. A total of 24.

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that the ongoing IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study met its primary endpoint.

Data presented at the World Congress on Treatment and Research in Multiple Sclerosis (WCTRIMS) demonstrated that early initiation of Betaseron(R) (interferon beta-1b) treatment had a greater impact on long-term outcomes, when compared to delayed treatment.

Bayer HealthCare Pharmaceuticals Inc. announced that Betaseron(R)* (interferon beta-1b), its treatment for relapsing forms of multiple sclerosis (MS), will soon be available with a new 30-gauge needle, which will be the thinnest needle of any injectable disease-modifying therapy for people with MS. The new needle is as thin as the needle commonly used for insulin and pediatric injections.

Results from a new study investigating the benefits of Sativex in neuropathic pain in people with multiple sclerosis (MS) have shown it gave long-term pain relief. The study followed 42 people with MS who took Sativex - a cannabis-based drug trialled by GW Pharmaceuticals. This